Abstract: A method of enhancing the presence of alternatively-spliced UMOD protein by inducing exon-skipping of a AS-UMOD m-RNA to protect TAL cells of kidneys in a patient suffering from acute kidney injury or chronic kidney disease.

Abstract: Methods and compositions comprising hematopoietic growth factor proteins and/or protein analogs thereof and/or combinations thereof and angiotensin converting enzyme inhibitors to treat the acute and long term adverse effects of radiation exposure in subjects who have been or will be exposed to radiation are disclosed.

Abstract: A method and apparatus for encoding/decoding a neural network-based personalized speech are provided. The method includes outputting a first bit stream in which an input speech signal is encrypted, based on the input speech signal, and outputting a second bit stream in which speaker information of the input speech signal is encrypted, based on the input speech signal.

Abstract: A method and device for encoding/decoding an audio signal based on dequantization through potential diffusion are provided. The method of decoding an audio signal includes obtaining a discrete latent vector in which a speech signal is quantized and based on the discrete latent vector, outputting a continuous latent vector in which the discrete latent vector is dequantized.

Abstract: Aspects of the present disclosure relate to novel medical compositions and methods of using same. In certain aspects, the disclosure relates to methods preventing acute kidney injury in a patient associated with increased amount of protein in the urine (e.g. albuminuria). In certain embodiments, the disclosure provides methods of preventing or treating acute kidney injury in a patient receiving a nephrotoxic drug, by administration of a reversible endocytosis inhibitor.

Abstract: Disclosed are methods to treat a renal disorder in a mammal in need thereof by administering to the mammal in need of treatment an effective amount of a store operated calcium entry (SOCE) inhibitor or a pharmaceutically acceptable salt thereof.

Abstract: The device of the present disclosure is configured for laparoscopic use, particularly to insert a fastener into a plate at an angle of up to 180° from the plane of insertion. The device is further configured to carry a plurality of fasteners, a tightening tool, a cutting device, and tweezers simultaneously to facilitate a rapid procedure while lessening the chance of infection by limiting the amount of times the device must be removed and re-inserted.

Abstract: A training method and device for estimating depth information of an image are disclosed. The training method may include obtaining depth information of a first image according to a resolution based on the first image, and outputting a per-pixel depth error of the first image based on the depth information of the first image, depth information of a second image, and camera parameters.

Abstract: Provided herein are genetically modified pigs, porcine organs, tissue, and cells having a reduced propensity to cause a rejection response in a human subject following xenotransplantation. In particular, provided herein are genetically modified pigs lacking nonGal xenoantigens, and porcine cells, tissues, and organs obtained from such genetically modified pigs that are suitable for transplantation into a human. Also provided herein are methods of improving a rejection related symptom in a human subject.

Abstract: An improved nanocomposite cathode material for lithium-ion batteries and method of making the same. The nanocomposite cathode material includes lithium iron silicate based nanoparticles with a conductive matrix of graphene sheets. The nanoparticles may be doped with at least one anion or cation.

Abstract: Disclosed herein are methods for producing interfering RNA biopesticides, such as microbial host organisms engineered to produce interfering RNA molecules which inhibit the expression of a gene in a mosquito disease vectors by RNA interference. Also disclosed herein are polynucleotides, such as expression cassettes encoding such interfering RNA molecule and facilitating integration, such as stable integration into the host organism's genome. Further disclosed herein are compositions including the disclosed nucleotide sequences and host organisms, along with methods of using the same to control mosquito populations.

Abstract: Disclosed herein are methods for using dual amplification of MYC and HSF1 in cancer cells to identify cancer cells having increased susceptibility to a therapeutic inhibitor. Disclosed herein are methods for treating a patient with cancer where the cancer cells have coamplification of MYC and HSF1. Also disclosed are methods for identifying therapeutic target and therapeutic compounds by screening with cells known to have dual amplification of MYC and HSF1.

Abstract: Stands for measuring proprioception comprising a hand layer comprising one or more vertically offset portions configured to ensure proper placement of a patient's hand in a predetermined position, a top cover coupled to the hand layer, wherein the top cover is designed to obscure the patient's view of the patient's hand, and a support element coupled to the hand layer and configured to support the hand layer at a predetermined angle are disclosed. Methods for measuring proprioception are also disclosed.

Abstract: A TAT-FXN fusion polypeptide useful in treating subjects diagnosed with Friedrich's Ataxia, hypertrophic cardiomyopathy, or both are disclosed, as are related methods of treatment and pharmaceutical compositions.

Abstract: Embodiments herein report compositions, methods, uses and manufacturing procedures for rotavirus constructs and immunogenic compositions thereof. Some embodiments concern compositions that include, but are not limited to, chimeric rotaviruses of use in immunogenic compositions against rotavirus infection as well as against other pathogenic virus infection in a subject. In certain embodiments, constructs of use herein can be generated and used where a rotavirus expression system further includes one or more nucleic acid molecules encoding one or more polypeptides of another pathogen (e.g. another enteric or mucosal pathogen).

Abstract: Various aspects and embodiments disclosed herein relate generally to the modelling, treatment, reducing resistence to the treatment, prevention, and diagnosis of diseases/symptoms induced by multiple myeloma. Embodiments include methods of treating a bone related disease, comprising the steps of: administering to a subject at least one therapeutically effective dose of a compound disclosed herein.

Abstract: Methods of treating a valvular heart disease are provided. Methods for treating valvular heard disease include administering to a subject a therapeutically effective amount of at least one hedgehog pathway inhibitor. Also provided are methods for reducing fibrosis in a subject, which comprise administering to the subject a therapeutically effective amount of at least one hedgehog pathway inhibitor.

Abstract: Methods for treating various cancers by administering one or more compounds that target the dimeric protein survivin are disclosed. Pharmaceutical compositions containing such compounds are also disclosed, along with general methods of identifying anti-cancer compounds that target oncogenic dimeric proteins. Exemplary compounds that can be used in the disclosed methods of treatment and pharmaceutical compositions have the chemical structures disclosed in the specification.

Abstract: Methods of treating a disease, disorder or syndrome associated with a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (such as COVID-19) in a subject by administering one or more C-X-C chemokine receptor 3 (CXCR3) antagonist peptides are described. Diagnostic methods for enhancing replication of SARS-CoV-2 in cultured cells and/or detecting the presence of SARS-CoV-2 in cultured cells by contacting the cells with a CXCR3 agonist peptide are also described.

Abstract: Genetically modified mice characterized by one or more symptoms or signs associated with expression of human APOE4p and mouse Trem2p and relevant to non-familial late-onset Alzheimer's disease are provided wherein the genome of the mouse includes: 1) a DNA sequence encoding a human APOE4 protein (APOE4p) operably linked to a promoter; and 2) a DNA sequence encoding a mouse Trem2 protein having a mutation p.R47H (Trem2p) operably linked to a promoter, such that the mouse expresses human APOE4p and mouse Trem2p. Methods are provided for screening for a compound for use in the treatment of Alzheimer's disease using such genetically modified mice.